Arachidonic acid-modified lovastatin discoidal reconstituted high density lipoprotein markedly decreases the drug leakage during the remodeling behaviors induced by lecithin cholesterol acyltransferase

Pharmaceutical Research

Volumn 31, Issue 7, 2014, Pages 1689-1709

  He, Hongliang ^a   Liu, Lisha ^a   Bai, Hui ^b   Wang, Ji ^a   Zhang, Yan ^b   Zhang, Wenli ^a   Zhang, Mengyuan ^a   Wu, Zimei ^c   Liu, Jianping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

arachidonic acid; d rHDL; drug leakage; LCAT; remodeling behaviors

Indexed keywords

APOLIPOPROTEIN A1; ARACHIDONIC ACID; CD36 ANTIGEN; CHOLESTEROL; CHOLESTEROL ESTER; DISCOIDAL RECONSTITUTED HIGH DENSITY LIPOPROTEIN; DRUG CARRIER; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; MESSENGER RNA; MEVINOLIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; CHEMICAL MODIFICATION; CHOLESTEROL TRANSPORT; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOAM CELL; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PARTICLE SIZE; PHOSPHOLIPID BILAYER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; HUMAN; METABOLISM;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARACHIDONIC ACID; CELL LINE; DRUG CARRIERS; FOAM CELLS; HUMANS; LIPOPROTEINS, HDL; LOVASTATIN; MACROPHAGES; MICE; MODELS, MOLECULAR; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RECOMBINANT PROTEINS;

EID: 84904248367     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1273-3     Document Type: Article

References (40)

1. Damiano MG, Mutharasan RK, Tripathy S, McMahon KM, Thaxton CS. Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev. 2012. doi: 10.1016/j.addr.2012.07.013.
2. Ding Y, Wang W, Feng M, Wang Y, Zhou J, Ding X, et al. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials. 2012;33(34):8893-905.
3. McMahon KM, Mutharasan RK, Tripathy S, Veliceasa D, Bobeica M, Shumaker DK, et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano letters. 2011;11(3):1208-14.
4. Shin J-Y, Yang Y, Heo P, Lee J-C, Kong B, Cho JY, et al. pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. Int J Nanomedicine. 2012;7:2805-16.
5. Jia J, Xiao Y, Liu J, Zhang W, He H, Chen L, et al. Preparation, characterizations, and in vitro metabolic processes of paclitaxel loaded discoidal recombinant high density lipoproteins. Journal of pharmaceutical sciences. 2012;101(8):2900-8.
6. Zhang W, He H, Liu J, Wang J, Zhang S, Zhang S, et al. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials. 2012;34(1):306-19.
7. Gu X, Zhang W, Liu J, Shaw JP, Shen Y, Xu Y, et al. Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells. AAPS PharmSciTech. 2011;12(4):1200-8.
8. Brewer Jr HB. High-Density Lipoprotein Metabolism. Atlas of Atherosclerosis and Metabolic Syndrome: Springer; 2011. p. 93-111.
9. Sviridov D. High density lipoproteins: structure, metabolism, function and TherapeuticsBy anatol kontush and M. John Chapman. Chem Med Chem. 2013;8(4):669-70.
10. Wang J, Jia J, Liu J, He H, Zhang W, Li Z. Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins. Drug Delivery. 2013;0:1-8.
11. Zhang M, Jia J, Liu J, He H, Liu L. A novel modified paclitaxel-loaded discoidal recombinant high-density lipoproteins: preparation, characterizations and in vivo evaluation. Asian Journal of Pharmaceutical Sciences. 2013.
12. Huggins KW, Curtiss LK, Gebre AK, Parks JS. Effect of long chain polyunsaturated fatty acids in the sn-2 position of phosphatidylcholine on the interaction with recombinant high density lipoprotein apolipoprotein AI. Journal of lipid research. 1998;39(12):2423-31.
13. Sparks DL, Chatterjee C, Young E, Renwick J, Pandey NR. Lipoprotein charge and vascular lipid metabolism. Chemistry and physics of lipids. 2008;154(1):1-6.
14. Zhang W-L, Xiao Y, Liu J-P, Wu Z-M, Gu X, Xu Y-M, et al. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. International journal of pharmaceutics. 2011;419(1):314-21.
15. Rye K-A, Hime NJ, Barter PJ. The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J Biol Chem. 1996;271(8):4243-50.
16. Kontogiannopoulos KN, Assimopoulou AN, Dimas K, Papageorgiou VP. Shikonin loaded liposomes as a new drug delivery system: physicochemical characterization and in vitro cytotoxicity. Eur J Lipid Sci Technol. 2011;113(9):1113-23.
17. Su Z, Niu J, Xiao Y, Ping Q, Sun M, Huang A, et al. Effect of octreotide-polyethylene glycol (100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Molecular pharmaceutics. 2011;8(5):1641-51.
18. Yang L, Ling W, Ma J, Tang Z, Wu C. Effect of lysophosphatidylcholine on cholesterol efflux from macrophage foam cells. Chinese Journal of Pathophysiology. 2002;18(1):28-31.
19. Murakami T, Wijagkanalan W, Hashida M, Tsuchida K. Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles. Nanomedicine. 2010;5(6):867-79.
20. Hofnagel O, Luechtenborg B, Weissen-Plenz G, Robenek H. Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochimica et biophysica acta (BBA)-molecular and cell biology of. Lipids. 2007;1771(9):1117-24.
21. Lin J, Li M, Wang Z, He S, Ma X, Li D. The role of CD4+ CD25+ regulatory T cells in macrophage-derived foam-cell formation. Journal of lipid research. 2010;51(5):1208-17.
22. Xu G, Watanabe T, Iso Y, Koba S, Sakai T, Nagashima M, et al. Preventive effects of heregulin-β1 on macrophage foam cell formation and atherosclerosis. Circulation research. 2009;105(5):500-10.
23. Zhao Z-Z, Wang Z, Li G-H, Wang R, Tan J-M, Cao X, et al. Hydrogen sulfide inhibits macrophage-derived foam cell formation. Experimental Biology and Medicine. 2011;236(2):169-76.
24. Liu G, Ma S, Li S, Cheng R, Meng F, Liu H, et al. The highly efficient delivery of exogenous proteins into cells mediated by biodegradable chimaeric polymersomes. Biomaterials. 2010;31(29):7575-85.
25. Xu S, Liu Z, Huang Y, Le K, Tang F, Huang H, et al. Tanshinone II- A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation. Transl Res. 2012;160(2):114-24.
26. Sung HJ, Kim J, Kim Y, Jang S-W, Ko J. N-acetyl cysteine suppresses the foam cell formation that is induced by oxidized low density lipoprotein via regulation of gene expression. Molecular biology reports. 2012;39(3):3001-7.
27. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Investig. 2004;114(4):582-8.
28. Ishii T, Itoh K, Ruiz E, Leake DS, Unoki H, Yamamoto M, et al. Role of nrf2 in the regulation of cd36 and stress protein expression in murine macrophages activation by oxidatively modified LDL and 4-hydroxynonenal. Circulation research. 2004;94(5):609-16.
29. Xie C, Kang J, Chen J-R, Lazarenko OP, Ferguson ME, Badger TM, et al. Lowbush blueberries inhibit scavenger receptors CD36 and SR- A expression and attenuate foam cell formation in ApoE-deficient mice. Food & Function. 2011;2(10):588-94.
30. Hrboticky N, Draude G, Hapfelmeier G, Lorenz R, Weber P. Lovastatin decreases the receptor-mediated degradation of acetylated and oxidized LDLs in human blood monocytes during the early stage of differentiation into macrophages. Arteriosclerosis, thrombosis, and vascular biology. 1999;19(5):1267-75.
31. Pietsch A, Erl W, Lorenz RL. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochemical pharmacology. 1996;52(3):433-9.
32. Lin R, Liu J, Peng N, Yang G, Gan W, Wang W. Lovastatin reduces nuclear factor κB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull. 2005;28(9):1630-4.
33. 10). Pharmacology: Toxicology and Applied; 2013.
34. Obi C, Wysokinski W, Karnicki K, Owen WG, McBane RD. Inhibition of platelet-rich arterial thrombus in vivo acute antithrombotic effect of intravenous HMG-CoA Reductase therapy. Arteriosclerosis, thrombosis, and vascular biology. 2009;29(9):1271-6.
35. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovascular research. 2000;47(4):648-57.
36. Parks JS, Huggins KW, Gebre AK, Burleson ER. Phosphatidylcholine fluidity and structure affect lecithin: cholesterol acyltransferase activity. Journal of lipid research. 2000;41(4):546-53.
37. Rye K-A, Duong M, Psaltis MK, Curtiss LK, Bonnet DJ, Stocker R, et al. Evidence that phospholipids play a key role in pre-β apoA-I formation and high-density lipoprotein remodeling. Biochemistry. 2002;41(41):12538-45.
38. Stamler CJ, Breznan D, Neville TA, Viau FJ, Camlioglu E, Sparks DL. Phosphatidylinositol promotes cholesterol transport in vivo. Journal of lipid research. 2000;41(8):1214-21.
39. Tian L, Luo N, Zhu X, Chung B-H, Garvey WT, Fu Y. Adiponectin-AdipoR1/2- APPL1 signaling axis suppresses human foam cell formation: differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses. Atherosclerosis. 2012;221(1):66-75.
40. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis. Circ J. 2010;74:213-20.